2-[(二乙氧基磷酰)硫基]-N,N,N-三甲基乙铵 | 6736-03-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-[(二乙氧基磷酰)硫基]-N,N,N-三甲基乙铵
• 英文名称: echothiophate
• 英文别名: 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium
• CAS: 6736-03-4
• 化学式: C₉H₂₃NO₃PS
• 分子量: 256.326
• InChiKey: BJOLKYGKSZKIGU-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid
• 熔点：
  138.0 °C
• 溶解度：
  Soluble

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.8
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：目前没有关于在母乳喂养期间使用乙硫磷眼药水的相关信息。由于乙硫磷是一种季铵化合物，它不太可能进入母乳或到达婴儿的血液循环。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到关于哺乳母亲的相关已发布信息。在动物中，胆碱能药物会增加催产素的释放，并对血清催乳素有不同的影响。对于已经建立泌乳的母亲，其催乳素水平可能不会影响她的哺乳能力。

◉ Summary of Use during Lactation:No information is available on the use of echothiophate ophthalmic drops during breastfeeding. Because echothiophate is a quaternary ammonium compound, it is not likely to pass into the breastmilk or reach the bloodstream of the infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release, and have variable effects on serum prolactin. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

来源:Drugs and Lactation Database (LactMed)

吸收、分配和排泄

• 吸收

这种眼用药物可能会被系统吸收。

This ophthalmic medication may be systemically absorbed.

来源:DrugBank

安全信息

• 海关编码：
  2931900090

文献信息

• Echothiophate Iodide Process
  申请人：SHILPA MEDICARE LIMITED

  公开号：US20170002031A1

  公开（公告）日：2017-01-05

  The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET. The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.

  本发明涉及一种制备碘化乙胆碱（I）的过程。通过本发明的方法获得的碘化乙胆碱（I）以新的晶体形式形式-SET命名。根据本发明的碘化乙胆碱（I）制备过程是一种环保的过程，避免使用有害的溶剂体系，并提供高纯度的碘化乙胆碱（I）。具有高纯度的碘化乙胆碱（I）晶体形式-SET的药物组合物在治疗青光眼等眼部疾病方面具有用处。
• [EN] ECHOTHIOPHATE IODIDE PROCESS<br/>[FR] PROCÉDÉ D'IODURE D'ÉCHOTHIOPATE
  申请人：SHILPA MEDICARE LTD

  公开号：WO2015114470A1

  公开（公告）日：2015-08-06

  The present invention relates to a process for preparation of Echothiophate Iodide Echothiophate Iodide (I) obtained by the process of the present invention is obtained as crystalline form designated as Form-SET. (I) The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.

  本发明涉及一种制备Echothiophate Iodide的方法。根据本发明的方法获得的Echothiophate Iodide（I）以结晶形式形成，被指定为Form-SET。本发明的Echothiophate Iodide（I）制备方法是一种环保的方法，避免使用有害的溶剂体系，并提供高纯度的Echothiophate Iodide（I）。所述结晶Form-SET的高纯度Echothiophate Iodide（I）制药组合物在治疗青光眼等眼部疾病方面非常有用。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation
  申请人：Braincells, Inc.

  公开号：EP2275095A2

  公开（公告）日：2011-01-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。